Forsyth County Sheriff, Attorney General Urged to Investigate Wake Forest for "Planned Animal Cruelty" Involving Monkeys
The physicians write that they have 'never heard of a single medical center using monkeys' for this type of training.
Share
The Physicians Committee explained in its complaint that a whistleblower informed it that the course, scheduled for Aug. 4-7, will allow pediatricians in training and others to perform invasive procedures on young vervet monkeys weighing about 2-4 pounds. Among the most invasive procedures to be performed on the monkeys is intubation, in which trainees force a plastic tube through the animals' nasal passages or mouths and into their windpipes. The Physicians Committee points out that intubation can cause bleeding, scarring, injury to the vocal cords, and even fatal complications. Other procedures include inserting thin tubes into the animals' urethras—which can cause painful bladder infections and injuries to the urethra—and using a needle to insert a tube into the artery, which can cause bleeding, infection, and the forming of blood clots.
In a related letter sent July 24 to NIH Director Jay Bhattacharya, the group called the practice 'unjustifiable and possibly illegal,' pointing out that the animals to be used are part of a colony of vervets that received more than $1 million in funding from the agency earlier this year. It requested that the NIH instruct Wake Forest to cancel the course and halt funding for the colony.
The letter to the NIH, signed by a Harvard-trained pediatrician and other physicians, points out that no other pediatrics programs in the United States or Canada use animals. The physicians write that they have 'never heard of a single medical center using monkeys' for this type of training. In a corresponding letter to Wake Forest University School of Medicine Dean L. Ebony Boulware, MD, MPH, they urge her to cancel the upcoming course.
The letters to the NIH and Dean Boulware emphasize that most trainees to whom the course is offered never take part and that more than 200 pediatrics programs in the U.S. and Canada teach procedures with lifelike newborn simulators, which Wake Forest owns, and shadowing of senior physicians.
"I never harmed animals to become a pediatrician,' said Margaret Peppercorn, MD, FAAP, of Portsmouth, R.I., who signed the letter. 'The NIH should stop this course before it happens and cancel funding for this monkey colony that is failing to benefit patients.'
In the letter, Dr. Peppercorn and others point out the NIH's recent effort to prioritize human-based research methods and reduce the use of animals mean Wake Forest's vervet colony 'appears misaligned with the agency's evolving priorities.' The physicians point to experiments conducted using the colony related to Alzheimer's, aging, obesity, and metabolic diseases that failed to benefit patients and that could have been done in humans or with human-relevant methods. One experiment forced 30 female vervets through a maze—including a pregnant monkey who carried her infant during the test—only to conclude that older animals walked slower. A paper published about the experiment acknowledged that numerous human clinical studies have been conducted on the issue but dismissed those studies as 'difficult and expensive.'
To see the letter to NIH or speak with Dr. Peppercorn or Physicians Committee Director of Academic Affairs John Pippin, MD, FACC, please contact Reina Pohl at 202-527-7326 or rpohl@pcrm.org.
Founded in 1985, the Physicians Committee for Responsible Medicine is a nonprofit organization that promotes preventive medicine, conducts clinical research, and encourages higher standards for ethics and effectiveness in research.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Pharma interest can plug NIH funding gap: Illumina CEO
Genetic sequencing company Illumina (ILMN) has had a rough few years. It has battled activist investors, faced off with the Federal Trade Commission, and, most recently, agreed to a $9.8 million settlement with the Department of Justice over a cybersecurity breach. To add to the pile: sanctions in China and the Trump administration cutting National Institutes of Health (NIH) funding, which the company relies heavily on for clinical research. The numbers don't lie. The stock is down more than 21% in the past year and sank more than 11% in after-hours trading Thursday after the company reported an earnings miss for the second quarter. The company reported $1.06 billion in revenues compared to expected revenues of $1.05 billion. Adjusted earnings per share came in at $1.19 compared to estimates of $1.01. But CEO Jacob Thaysen told Yahoo Finance he remains positive about the company's near-term growth. Why? Because, in part, pharmaceutical companies can provide a new market. "Now, we're shifting from small things to really big programs. Some of the things making up for the reduction from the NIH is kind of indirect, but pharma is getting more interest in these big programs," he said, noting that 15% of the company is exposed to government research funding. "It's not only about sequencing itself, but really using massive amounts of data ... to really identify new drug targets and understand a disease," Thaysen said. The idea to use patient data to help the pharmaceutical world was also identified by 23andMe, which recently came out of bankruptcy through a nonprofit led by founder Anne Wojcicki. Thaysen said that unlike 23andMe, which he has worked with, his company is not going to pursue drug development on its own. "We have a lot of pharma companies that are very excited to work with us," he said. In addition to genetic testing of patient samples, the company is looking at growing in the preventative side of care with cancer screenings. The oncology business, Thaysen said, will have healthy growth over the next 10 or so years. China China banned importations of the San Diego-based company's sequencing machines earlier this year as part of its retaliatory actions to Trump's tariff war. Thaysen said he is working with regulators to try to reverse that, but "in the meantime, that business is declining, and we are expecting it to be flat." In fact, though China has historically been about 10% of the company's business, it contributed to half of the decline in earnings this past week. "China was never a huge part of Illumina's business. When it was the largest, it was just around 10%. We're down to 5% of the business," Thaysen told Yahoo Finance. But because of the tariff war and China's goals to boost its domestic innovation market, Illumina has faced a setback in its market power there from local competition. "As soon as there is a Chinese alternative that is good enough, then you will see that the Chinese government is pushing for the Chinese population, the Chinese companies to use that technology," Thaysen said. He added that even with the increased competition, China is an appealing market to remain in. Analysts are still waiting to see more progress on Illumina's return to growth. Jefferies analyst Tycho Peterson said in a note to clients that the firm will reiterate its Hold rating until things settle: "While the clinical traction is encouraging, we view clarity on near-term headwinds (A&G, China, Roche) and a path to sustainable HSD growth as key to a more constructive view. Reiterate Hold." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNN
a day ago
- CNN
Judge pauses termination of LGBTQ+ health research grants
LGBTQ issuesFacebookTweetLink Follow A federal judge on Friday blocked the Trump administration's cancelation of US National Institutes of Health grants that research on LGBTQ+ related health issues. Ruling from the bench, US District Judge Lydia Griggsby, an appointee of former President Joe Biden, said she would issue a preliminary injunction against NIH directives to terminate grants for LGBTQ+ health research, describing such directives as designed to 'focus and target LGBTQ+ members.' 'It's clear that why the funding is being terminated and why the grants will not move forward is because they relate to that community,' Griggsby said. The lawsuit, filed in May by the American Association of Physicians for Human Rights, against the NIH and Department of Health and Human Services alleges that in targeting only certain, predominantly LGBTQ+-related research projects for funding cuts, the NIH engaged in unlawful discrimination. In determining what grants to cut, Physicians for Human Rights attorney Omar Gonzalez-Pagan argued on Friday, NIH employees 'literally do a search term of projects, and they literally look for words' associated with LGBTQ+ related issues – including transgender, nonbinary, and sexuality. The reason the government is targeting transgender research projects 'is because they believe transgender people do not exist,' Omar Gonzalez-Pagan said. 'We need to take the government at its word,' he continued. 'That this a president of the United States who has spoken so denigratingly of the people that he governs' Assistant US Attorney Michael Wilson argued that the court lacked jurisdiction and would become 'involved in what should be a political process.' This is not the first time a district court has thwarted the NIH's attempts to cancel grants funding identity-related research. In a separate legal challenge to the case, a district court judge in Massachusetts ruled in June that the gutting of NIH grants in diversity-related fields is illegal, though that ruling addressed only a fraction of the hundreds of grants actually terminated. District Judge William Young, an appointee of former President Ronald Reagan, said it is 'palpably clear' that 'racial discrimination and discrimination against America's LGBTQ community' was behind the NIH's grant termination plans. Griggsby said she would issue a written ruling on the matter in the coming weeks.
Politico
a day ago
- Politico
Senate appropriators defend the NIH
WASHINGTON WATCH Senate appropriators came out hard in support of the National Institutes of Health on Thursday, giving the agency a $400 million funding boost for the 2026 fiscal year. How so: The Senate Appropriations Committee upped the agency's budget to $48.7 billion in the 2026 funding bill that cleared the panel with a 26-3 vote Thursday. If the bill becomes law, it would increase cancer research by $150 million; Alzheimer's research by $100 million and amyotrophic lateral sclerosis, or ALS, research by $25 million. The NIH's National Institute of Allergy and Infectious Diseases and the Office of Research on Women's Health would each get a $30 million boost. Research on maternal mortality, diabetes and rare diseases would also see an increase, among others. Why it matters: The funding boost is a rebuke from both Republicans and Democrats to the Trump administration's demand to decrease the NIH funding in the next fiscal year by as much as 40 percent, or $18 billion. Senate Appropriations Chair Susan Collins (R-Maine) said the legislation 'prioritizes funding to help make Americans healthier and supports life-saving medical research.' Sen. Patty Murray (D-Wash.), the top Democrat on the panel, said the budget increase was a message to 'the scientists wondering if there will even be an NIH by the end of this administration. This committee's resounding message is: 'Yes, Congress has your back.'' Murray urged scientists to continue their research in the U.S. despite the efforts of other countries to lure them away. The appropriators also adopted an amendment Thursday that would limit the Trump administration's control over NIH research funding. An amendment in the bill's manager's package limits the administration's plan to shift funding for most NIH grants from a multiyear schedule to an upfront single-year payment. The amendment states that no funds appropriated in the fiscal 2026 spending bill can be used to increase the proportion of grants fully funded in the first year of the award, compared with fiscal 2024. The NIH can only increase that proportion of forward-funded grants if the agency ensures it isn't cutting grants to do so. What's next: The bill is cleared for floor action. But congressional leaders haven't started bipartisan negotiations toward overall government funding totals, increasing the odds that lawmakers will again resort to a stopgap funding patch before the next fiscal year starts on Oct. 1. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Peacock feathers have reflective structures that can amplify light into a laser beam, Science reports. Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. MORNING MONEY: CAPITAL RISK — POLITICO's flagship financial newsletter has a new Friday edition built for the economic era we're living in: one shaped by political volatility, disruption and a wave of policy decisions with sector-wide consequences. Each week, Morning Money: Capital Risk brings sharp reporting and analysis on how political risk is moving markets and how investors are adapting. Want to know how health care regulation, tariffs, or court rulings could ripple through the economy? Start here. WORLD VIEW A draft United Nations plan to make the world healthier no longer includes several targets cracking down on sugary drinks, trans fats and tobacco to prevent and control noncommunicable diseases globally. Struck down: A target of 80 percent of countries taxing sugary drinks at levels recommended by the World Health Organization by 2030, POLITICO's Rory O'Neill reports. That goal was a pillar of the initial draft, which will take the form of a nonbinding political declaration world leaders are expected to endorse at a Sept. 25 meeting in New York, on the margins of the U.N. General Assembly. The latest version has also dropped commitments to eliminate trans fats and aims instead to reduce them to the 'lowest level possible.' It also requires front-of-pack labels with nutritional information. A requirement for health warnings on tobacco packaging to be graphic and accompanied by elements that make it unattractive to consumers is also gone. The new draft has softer language on tobacco advertising, requiring countries to restrict it instead of eliminate it. 'Make no mistake, the Declaration in its current form is a backslide,' said Alison Cox, director of policy and advocacy at the NCD Alliance, in a statement. The alliance is a Switzerland-based civil society group working to promote chronic disease prevention. Why it matters: World leaders aim to reduce premature mortality from noncommunicable diseases such as heart disease, cancer and diabetes by 2030 through prevention and treatment and to improve mental health and well-being globally. Noncommunicable diseases killed 18 million people under age 70 in 2021, according to the WHO. Most deaths were in low- and middle-income countries. The aims align with the U.S. Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again agenda, but it's unclear how much the U.S. is involved in drafting the final text. HHS did not respond to a request for comment. What's next: Negotiators are meeting this week in New York to discuss the text.
